Laboratory Investigation

Kidney International (1994) 45, 737–742; doi:10.1038/ki.1994.98

Effects of guanidino and uremic compounds on nitric oxide pathways

Raymond J MacAllister1, Guy St J Whitley1 and Patrick Vallance1

1Departments of Pharmacology and Clinical Pharmacology, and Cellular and Molecular Sciences, St. George's Hospital Medical School, London, England, United Kingdom

Correspondence: Dr Raymond MacAllister, Department of pharmacology and Clinical Pharmacology, St. George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, England, United Kingdom.

Received 19 April 1993; Revised 20 August 1993; Accepted 27 September 1993.

Top

Abstract

Effects of guanidino and uremic compounds on nitric oxide pathways. Aminoguanidine, NG-monomethyl-L-arginine (L-NMMA), NGNGdimethyl-L-arginine (asymmetric dimethylarginine; ADMA), creatinine, guanidinosuccinic acid, guanidinoproprionic acid and methylguanidine were added to cultures of activated murine macrophages. Only aminoguanidine, ADMA, L-NMMA and methylguanidine inhibited nitrite production in a dose-dependent manner. In the presence of 100 microM arginine, nitrite production was inhibited by 31.8 plusminus 7.1% by ADMA (100 microM; P < 0.01) but the same dose of methylguanidine was without effect. A higher dose of methylguanidine (1000 microM) inhibited nitrite production by 47.6 plusminus 5.6% (P < 0.001). The effects of these compounds were also tested on relaxation of human saphenous veins. L-NMMA and ADMA inhibited endothelium-dependent relaxations (EC50 = 4.7 plusminus 1.1 microM and 17.9 plusminus 4.9 microM, respectively); methylguanidine caused endothelium-independent contractions and reversed the relaxations to bradykinin and sodium nitroprusside (EC50 > 100 microM); aminoguanidine was without effect. The results of this study suggest that of the guanidino compounds which accumulate in renal failure, only ADMA is a potent inhibitor of nitric oxide (NO) synthesis. Methylguanidine is a weak inhibitor of nitric oxide synthesis, whereas the closely related compound aminoguanidine appears to inhibit selectively the inducible isoform of nitric oxide synthase and has no effect on constitutive NO synthase in human veins.

Top

References

  1. Rees DD, Palmer RM, Moncada S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 86:3375–3378, 1989 | Article | PubMed | ChemPort |
  2. Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2:997–1000, 1989 | Article | PubMed | ChemPort |
  3. Stuehr DJ, Marletta MA: Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines or interferon-gamma. J Immunol 139:518–525, 1987 | PubMed | ISI | ChemPort |
  4. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S: Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144:4794–4797, 1990 | PubMed | ISI | ChemPort |
  5. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572–575, 1992 | Article | PubMed | ISI | ChemPort |
  6. Fickling S, Leone A, Nussey S, Vallance P, Whitley G: Synthesis of NGNG dimethylarginine by human endothelial cells. Endothelium 1:137–140, 1993
  7. May RC, Kelly RA, Mitch WE: Pathophysiology of uremia, in The Kidney, edited by Brenner BM, Rector FC, (5th ed), Philadelphia, Saunders, 1991, pp 1997–2018
  8. DiRosa M, Radomski MW, Carnuccio R, Moncada S: Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun 172:1246–1252, 1990 | PubMed | ChemPort |
  9. Green L, Wagner D, Glogowski J, Skipper T, Wishnok J, Tannenbaum S: Analysis of nitrate, nitrite, and 15N-nitrate in biological fluids. Anal Biochem 126:131–138, 1982 | Article | PubMed | ISI | ChemPort |
  10. Hibbs JB Jr, Vavrin Z, Taintor RR: L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 138:550–565, 1987 | PubMed | ISI | ChemPort |
  11. Sessa WC, Hecker M, Mitchell JA, Vane JR: The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial cells. Proc Natl Acad Sci USA 87:8607–8611, 1990 | PubMed | ChemPort |
  12. Lüscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, Von Segesser L, Yang ZH, Turina M, Gradel E, Weber E, Bühler FR: Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 319:462–467, 1988 | PubMed | ISI | ChemPort |
  13. Yang Z, Richard V, Lüscher TF: Endothelium-derived nitric oxide in human arteries and veins, in Nitric Oxide from L-arginine: A Bioregulatory System, edited by Moncada S, Higgs EA, Amsterdam, Elsevier, 1990, pp. 89–93
  14. Furchgott RF, Jothianandan D, Freay AD: Endothelium-derived relaxing factor: Some old and new findings, in Nitric Oxide from L-arginine: A Bioregulatory System, edited by Moncada SH, Higgs EA, Amsterdam, Elsevier, 1990, pp. 5–17
  15. Brenner BM, Yu ASL: Uraemic syndrome revisited: A pathogenetic role for retained endogenous inhibitors of nitric oxide synthesis. Curr Opin Nephrol Hypertens 1:3–7, 1992
  16. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101:746–752, 1990 | PubMed | ISI | ChemPort |
  17. Tilton RG, Chang C, Hasan KS, Smith SR, Petrash MJ, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR: Prevention of diabetic vascular dysfunction by guanidines; inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221–232, 1993 | PubMed | ISI | ChemPort |
  18. Thomas G, Ramwell PW: Identification of guanidino succinate as a putative source of the endothelium derived relaxing factor. Biochem Biophys Res Commun 183:584–589, 1992 | Article | PubMed | ISI | ChemPort |
  19. Haddy FJ: Potassium, Na+-K+ pump inhibitor and low-renin hypertension. Clin Invest Med 107:547–554, 1987
  20. Krayer O, Weiner N, Mosimann W: Blood norepinephrine levels during responses of the heart-lung preparation to methylguanidine. J Pharmacol Exp Ther 181:108–115, 1972
  21. Cubeddu L, Mosimann W, Weiner N: The effect of methylguanidine on norepinephrine metabolism in isolated perfused spleen and heart. J Pharmacol Exp Ther 188:93–106, 1973
  22. Gäng V, Berneburg H, Hennemann H, Hevendehl G: Diamine oxidase (histaminase) in chronic renal disease and its inhibition in vitro by methylguanidine. Clin Nephrol 3:171–177, 1976
  23. Major RH: The possible relationship between guanidin and high blood pressure. Am J Med Sci 83:81–84, 1925
  24. Taylor G, Unwin R, Wilkins M, Capasso G: Arginine derivitives and uraemia. (letter) Lancet 339:1243–1243, 1992 | Article | PubMed | ChemPort |
  25. Johns RA, Moscicki JC, Difazio CA: Nitric oxide synthase inhibitor dose-dependently and reversibly reduces the threshold for halothane anesthesia. A role for nitric oxide in mediating consciousness? Anesthesiology 77:779–784, 1992 | PubMed | ISI | ChemPort |
  26. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90:278–281, 1992 | PubMed | ISI | ChemPort |
  27. Noris M, Benigni A, Boccardo P, Aiello S, Gaspari F, Todeschini M, Figliuzzi M, Remuzzi G: Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney Int 44:445–450, 1993 | PubMed | ISI | ChemPort |
  28. Zoja C, Noris M, Corna D, Vigano G, Perico G, Degaetano G, Remuzzi G: L-arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uraemia. Lab Invest 65:479–483, 1991 | PubMed | ChemPort |

Extra navigation

.
ADVERTISEMENT